Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
BIOTISSUE HOLDINGS INC. has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 5 distinct examiners across 4 distinct art units. WESTON, ALYSSA G is the busiest examiner with 1 pending action. Each of the 5 pending office actions is being reviewed by a different individual.
The presence of 5 distinct examiners for the 5 pending office actions indicates a fragmented prosecution landscape. The 4 distinct art units show that the work is spread across several technical categories within the Biotechnology & Pharmaceuticals field. WESTON, ALYSSA G is one of the many individuals each managing 1 pending action. This structure requires the company to interact with different people, each potentially having a unique examination style. The variety of groups shows that the personnel are distinct across the cases. Practitioners should be prepared for a decentralized environment where every action is reviewed by a different person. The portfolio relies on the input of the 5 distinct examiners across the 4 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WESTON, ALYSSA G | 1 | 59.8% | +50.9% |
| PAULUS, ERIN VIRGINIA | 1 | 21.1% | +93.8% |
| MOSS, NATALIE M | 1 | 30.8% | +17.1% |
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
| BATES, KEENAN ALEXANDER | 1 | 45.5% | +79.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033470 | METHODS FOR PROCESSING FETAL SUPPORT TISSUE | PAULUS, ERIN VIRGINIA | 27d |
| 19353469 | COMPOSITIONS, DEVICES, AND METHODS RELATING TO USE OF AN AMNIOTIC MEMBRANE FETAL TISSUE PRODUCT | WESTON, ALYSSA G | — |
| 17291070 | METHODS OF CELLULAR REPROGRAMMING | BATES, KEENAN ALEXANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033470 | METHODS FOR PROCESSING FETAL SUPPORT TISSUE | PAULUS, ERIN VIRGINIA | 27d |
| 19353469 | COMPOSITIONS, DEVICES, AND METHODS RELATING TO USE OF AN AMNIOTIC MEMBRANE FETAL TISSUE PRODUCT | WESTON, ALYSSA G | — |
| 17914691 | METHODS OF USING UMBILICAL CORD PRODUCTS FOR TREATMENT OF OCULAR SURFACE DISORDERS | MOSS, NATALIE M | — |
| 17620650 | METHODS OF PROMOTING VASCULOGENESIS | JOHNSON, ALLISON MARIE | — |
| 17291070 | METHODS OF CELLULAR REPROGRAMMING | BATES, KEENAN ALEXANDER | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1633 | 1 |
| 1653 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19353469 | COMPOSITIONS, DEVICES, AND METHODS RELATING TO USE OF AN AMNIOTIC MEMBRANE FETAL TISSUE PRODUCT | WESTON, ALYSSA G | 1633 | §102§103 | Final Rejection | — | Pending | Oct 08, 2025 |
| 18033470 | METHODS FOR PROCESSING FETAL SUPPORT TISSUE | PAULUS, ERIN VIRGINIA | 1631 | §103 | Final Rejection | 27d | Pending | Apr 24, 2023 |
| 17914691 | METHODS OF USING UMBILICAL CORD PRODUCTS FOR TREATMENT OF OCULAR SURFACE DISORDERS | MOSS, NATALIE M | 1653 | §103 | Non-Final OA | — | Pending | Sep 26, 2022 |
| 17620650 | METHODS OF PROMOTING VASCULOGENESIS | JOHNSON, ALLISON MARIE | 1638 | §112 | Non-Final OA | — | Pending | Dec 17, 2021 |
| 17291070 | METHODS OF CELLULAR REPROGRAMMING | BATES, KEENAN ALEXANDER | 1631 | §103§112 | Non-Final OA | — | Pending | May 04, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial